Last reviewed · How we verify
NCT05887245
Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy
trial in Renal Cell Carcinoma in 200 participants. Participants enrolled and being followed up; not accepting new ones.
17 April 2025
Quick facts
| Lead sponsor | Centre of Postgraduate Medical Education |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 17 April 2023 |
| Primary completion | 17 April 2025 |
| Estimated completion | 1 January 2030 |
| Sites | 1 location across Poland |
Conditions studied
- Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →
- Kidney Neoplasm — all drugs for Kidney Neoplasm →
- Urologic Neoplasms — all drugs for Urologic Neoplasms →
- Urogenital Neoplasms — all drugs for Urogenital Neoplasms →
Sponsor
Centre of Postgraduate Medical Education — full company profile →
Who can join
18 and older, any sex, with Renal Cell Carcinoma or Kidney Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to gain a better understanding of the phenomenon of adherent perinephric fat (APF), which occurs in some patients undergoing partial nephrectomy (PN). This phenomenon, so-called "toxic fat", is a commonly recognized problem among urologists, but its significance has not yet been fully understood. The study aims to identify new clinical risk factors for APF occurrence and evaluate its impact on functional, perioperative, and oncological treatment outcomes. The study will be conducted on patients who are qualified for PN surgery. Prior to the surgical procedure, venous blood will be collected, which will be used for various measurements, such as blood morphology, kidney parameters, inflammation markers, liver function tests, glucose, and lipid profile. In addition, medical data will be collected concerning the patient's overall health, observed changes in the kidney, perioperative course, hospitalization, and histopathological characteristics of the tumor. After treatment, patients will be followed up for up to 60 months. The knowledge gained from this study can significantly assist in making decisions about surgical treatment and thus contribute to improving the treatment outcomes of patients with kidney tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05887245
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Cell Carcinoma
Currently open trials in the same condition.
- NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
- NCT07195682 — A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) · Phase 1 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07227402 — A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6 · Phase 3 · recruiting
- NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
Other Centre of Postgraduate Medical Education trials
Trials by the same sponsor.
- NCT07358299 — Haemodynamic Effects and Complications of Continuous Versus Single-shot Spinal Anaesthesia for HIP Fracture Surgery · Phase 4 · not yet recruiting
- NCT07197398 — Preoperative Data and the Spinal Spread of Local Anesthetic in Cesarean Section · recruiting
- NCT06741410 — Ephedrine Versus Phenylephrine for Spinal Block - Related Hypotension in Cesarean Delivery · completed
- NCT06418516 — Early Detection of Esophageal Squamous Cancer With the Capsule Sponge Device · NA · not yet recruiting
- NCT06472102 — Cardioneuroablation: Fragmented Atrial Potentials, Intracardiac Echocardiography and Computed Tomography · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05887245 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre of Postgraduate Medical Education
- Last refreshed: 27 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05887245.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing